Products for Research Use Only

Mirzotamab

CAT: 0804-HY-P99740-01Size: 1 mgDry Ice: YesHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P99740-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Mirzotamab is an IgG1κ monoclonal antibody targeting to CD276/B7-H3 with anti-tumor activity. Mirzotamab conjugates with Clezutoclax , a BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC)[2][3].
CAS Number
2229859-11-2
UNSPSC
12352203
Target
ADC Antibody; CD276/B7-H3
Type
Inhibitory Antibodies
Related Pathways
Antibody-drug Conjugate/ADC Related; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/mirzotamab.html
Purity
99.45
Solubility
10 mM in DMSO
Smiles
[Mirzotamab]
Molecular Weight
(144.86 kDa)
References & Citations
[1]Tolcher A W, et al. A first-in-human study of mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed/refractory solid tumors: Dose escalation results. 2021. |[2]Cai Jiaqiang, et al. Antibody-drug conjugate containing BCL-2 family proteolysis agent, preparation method therefor, and use thereof. WO2024153185. 2024.07.25.|[3]Nathanson, David A., et al. Combination therapy for treating glioblastoma. WO2022231996. 2022.11.03.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported